Pharmacometrics & Pharmacokinetics (PMK) Community

Description & Goals

The Pharmacometrics & Pharmacokinetics (PMK) Community represents a diverse group of scientists from pharmaceutical industry, government, and academia who are interested in the science of clinical pharmacology, pharmacokinetics/pharmacodynamics (PK/PD) and pharmacometrics as disciplines to spur the research and development of safe and effective therapeutics.

The mission of the PMK Community is to promote interaction and knowledge sharing of novel application of clinical pharmacology, PK/PD and pharmacometric approaches that can be utilized to accelerate drug discovery and development of innovative new medicines. We accomplish our mission by:

Education: Educational and knowledge sharing platforms on trending topics (e.g., new modalities, advanced analytics, real-world data, etc.) in clinical pharmacology, PK/PD and pharmacometrics via ASCPT’s Annual Meeting and webinars. This helps to enhance and accelerate the decision making in drug development.
Engagement: Promoting the engagement of Community members through collaboration, volunteer, and outreach opportunities. These efforts stimulate the connection among diverse PMK members and further grow the PMK Community.
Collaboration: Stimulating collaboration between the PMK Community and other ASCPT Communities (e.g., Regulatory Science, Biologics, Oncology) to advance the field of pharmacometrics, PK/PD and clinical pharmacology.

Community Connection

Join the LinkedIn Group.

Past Webinars

The webinars below can be accessed in the Members Only Webinar Library: Access Library

We Are All Patients
The Application of Clinical Pharmacology for the Treatment of Rare Diseases
The US Food & Drug Administration's Perspective on Immunogenicity
In Vitro-In Vivo Correlation for Drug-Drug Interactions with Rosuvastatin
Introduction of Deep Learning in Drug Discovery and Development, Part 3 – Computer Vision with Convolutional Neural Networks (CNNs)
Introduction of Deep Learning in Drug Discovery and Development, Part 2: Artificial Neural Networks (ANNs)
A Semi-Mechanistic PK/PD Model to Project Undetectable Minimal Residual Disease Rates in Chronic Lymphocytic Leukemia Studies
Model-Informed Drug Development (MIDD): Collaboration to Streamline New Drug Development
Clinical Pharmacology Considerations for Antibody Drug Conjugates
Introduction of Deep Learning in Drug Discovery and Development Part 1
Effective Visual Communication for Quantitative Scientists, Part 2
Effective Visual Communication for Quantitative Scientists, Part 1
Powering Clinical Pharmacology Analytics into the Digital Age with Machine Learning and Artificial Intelligence
Cellular Kinetic and Exposure-Response Analysis to Support Dose selection of CAR-T therapy (Tisagenlecleucel)
A Genetic Algorithm Based Global Search Strategy for Population Pharmacokinetic/Pharmacodynamic Model Selection